Bristol Myers Squibb Just Got Some Great Regulatory News
It's no secret that Bristol Myers Squibb (NYSE: BMY) will need to innovate to grow as its three top drugs -- Revlimid, Eliquis, and Opdivo -- face patent expirations during the next decade. Fortunately, Bristol Myers Squibb got great news from a major European regulatory agency earlier this month.
The Committee for Medicinal Products for Human Use (CHMP) recommended that Bristol Myers Squibb's Zeposia be approved to treat adults with moderately to severely active ulcerative colitis who didn't respond to at least one other conventional therapy or biologic agent.
Let's dig into Zeposia's efficacy in treating patients with ulcerative colitis and why I believe this indication, which would be effective throughout the European Union if formally approved, could be a boon for Bristol Myers Squibb.
Source Fool.com
